CLINICIP

Improved survival chances for critically ill patients and increased efficiency and safety in clinical practice: CLINICIP clinicians and scientists have joined forces in order to develop an intelligent glucose monitoring and control system for critically ill patients.The CLINICIP system will help to improve the survival chances in intensive care units and to increase efficiency and safety in clinical practice.

Hyperglycaemia and insulin resistance are common in critically ill patients, even when glucose homeostasis has previously been normal. Recent medical studies brought evidence that treatment of high glucose levels with insulin will dramatically improve survival chances in these patients. However, treatment of glycaemia with target glucose levels close to physiological range is labour-intensive and although the cause/effect is well-known, the unmanageable workload and the prevalent fear of hypoglycaemiae among critical care physicians still prevent the general implementation of glycaemic control in the intensive care unit.

Therefore, the overall goal of CLINICIP is to establish glycaemic control on an automated basis in order to improve survival chances in intensive care units.

For further information, please visit:
http://www.clinicip.org

Project co-ordinator:
JOANNEUM RESEARCH Forschungsgesellschaft mbH

Partners:

  • JOANNEUM RESEARCH Forschungsgesellschaft mbH (AT)
  • Disetronic Medical Systems AG (CH)
  • Medizinische Universität Graz (AT)
  • Technische Universität Graz (AT)
  • Univerzita Karlova V Praze (CZ)
  • Royal Brompton and Harefield NHS Trust (UK)
  • Consiglio Nazionale delle Ricerche (IT)
  • SensLab Gesellschaft zur Entwicklung und Herstellung bioelektrochemischer Sensoren mbH (DE)
  • Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. (DE)
  • GAMBRO Dialysatoren GmbH (DE)
  • Katholieke Universiteit Leuven (BE)
  • The Chancellor, Masters and Scholars of the University of Cambridge (UK)
  • B.Braun Melsungen AG (DE)

Timetable: 01/04 - to 12/07

Total cost: € 11.256.588

EC funding: € 7.500.000

Instrument: IP

Project Identifier: IST-2002-506965

Most Popular Now

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...